Clopidogrel Discontinuation Before Wound Debridement
Discontinue clopidogrel exactly 5 days before wound debridement in patients without a recent coronary stent. 1, 2, 3
Critical Pre-Procedure Assessment
Before stopping clopidogrel, you must first determine coronary stent status:
Patients with a drug-eluting stent placed within the past 12 months should NOT discontinue clopidogrel without cardiology consultation, as abrupt cessation dramatically increases the risk of stent thrombosis, myocardial infarction, and death. 1
Patients with a bare-metal stent placed within the past 6 weeks also require cardiology consultation before any interruption, for the same thrombotic concerns. 1
When a recent stent is present, postpone elective debridement until the high-risk period has passed (>12 months for drug-eluting stents, >6 weeks for bare-metal stents), or perform the procedure while the patient remains on clopidogrel after cardiology clearance. 1
Standard 5-Day Discontinuation Protocol
For patients without recent coronary stents:
Stop clopidogrel exactly 5 days before the debridement procedure. This interval corresponds to the platelet lifespan (7-10 days) and yields approximately 50-70% recovery of platelet function, which is adequate for surgical hemostasis. 1, 2, 3
The FDA label explicitly states: "When possible, interrupt therapy with clopidogrel for five days prior to such surgery." 3
This 5-day recommendation carries ACC/AHA Class I, Level B evidence across multiple guideline documents. 1
Evidence Supporting the 5-Day Window
Stopping clopidogrel less than 5 days before surgery increases major bleeding (9.6% vs 6.3%) without providing a mortality benefit, as demonstrated in the CURE trial. 1
Clopidogrel produces irreversible platelet inhibition for the lifetime of the platelet (7-10 days), and approximately 10-14% of normal platelet function is restored for each day after discontinuation. 2, 3
After 5 days of discontinuation, roughly 50-70% of platelets will have normal function, which is generally sufficient for surgical hemostasis. 2
Aspirin Management
Continue low-dose aspirin (75-100 mg daily) throughout the perioperative period if the patient was on dual antiplatelet therapy (aspirin + clopidogrel). 1, 2
Aspirin alone does not significantly increase bleeding risk in most procedures and maintains essential antiplatelet protection while clopidogrel is held. 1
Post-Procedure Resumption
Restart clopidogrel within 24 hours after debridement once adequate hemostasis is confirmed, to minimize thrombotic risk. 1, 2
The FDA label states: "Resume clopidogrel as soon as hemostasis is achieved." 3
Common Pitfalls to Avoid
Do not extend the discontinuation period to 7 days for routine wound debridement. The 7-day window is reserved for high-risk surgeries in closed spaces (intracranial neurosurgery, spinal surgery involving the medullary canal, or CABG), not for accessible wound debridement. 1, 4
Do not use platelet function testing to guide perioperative management, as it does not correlate with clinical outcomes and is not recommended. 1, 2
Do not use bridging therapy with glycoprotein IIb/IIIa inhibitors, cangrelor, or LMWH, as they do not protect against stent thrombosis and may increase bleeding. 2, 4